Astellas Eyes More U.S. Sales, Workforce Growth with New $150M North America HQ – Genetic Engineering News

However, Astellas fell short of its revised forecast for the fiscal year of ¥85 billion ($1.086 billion) in part due to increased competition from generics in the U.S. for its immunosuppressant Prograf. Its total sales fell 4.8% to ¥154.8 …